Filing Details
- Accession Number:
- 0001140361-25-007173
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-05 16:01:55
- Reporting Period:
- 2025-03-03
- Filing Date:
- 2025-03-05
- Accepted Time:
- 2025-03-05 16:01:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1124105 | Gyre Therapeutics Inc. | GYRE | Pharmaceutical Preparations (2834) | 562020050 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1985547 | Songjiang Ma | C/O Gyre Therapeutics, Inc. 12770 High Bluff Drive, Suite 150 San Diego CA 92130 | President | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2025-03-03 | 2,000 | $11.23 | 2,849,260 | No | 4 | S | Indirect | By Spouse |
Common Stock | Disposition | 2025-03-04 | 2,000 | $10.86 | 2,847,260 | No | 4 | S | Indirect | By Spouse |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Spouse |
No | 4 | S | Indirect | By Spouse |
Footnotes
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.95 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.03. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.